Renaissance Technologies LLC cut its holdings in shares of AtriCure Inc. (NASDAQ:ATRC) by 66.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,600 shares of the medical device company’s stock after selling 43,100 shares during the period. Renaissance Technologies LLC owned approximately 0.06% of AtriCure worth $757,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. purchased a new position in AtriCure during the 3rd quarter valued at $210,000. Engineers Gate Manager LP acquired a new position in shares of AtriCure in the third quarter valued at about $521,000. Campbell & CO Investment Adviser LLC increased its holdings in shares of AtriCure by 37.7% in the third quarter. Campbell & CO Investment Adviser LLC now owns 15,339 shares of the medical device company’s stock valued at $537,000 after purchasing an additional 4,200 shares during the period. PEAK6 Investments LLC acquired a new position in shares of AtriCure in the third quarter valued at about $559,000. Finally, AMS Capital Ltda acquired a new position in shares of AtriCure in the third quarter valued at about $725,000. 81.62% of the stock is currently owned by institutional investors.
NASDAQ:ATRC opened at $31.32 on Tuesday. AtriCure Inc. has a one year low of $15.14 and a one year high of $36.49. The company has a quick ratio of 1.96, a current ratio of 2.62 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $1.21 billion, a P/E ratio of -37.73 and a beta of 0.27.
A number of brokerages have recently commented on ATRC. Zacks Investment Research downgraded AtriCure from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. BidaskClub downgraded AtriCure from a “buy” rating to a “hold” rating in a research report on Thursday, January 31st. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $35.60.
ILLEGAL ACTIVITY WARNING: This story was reported by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/renaissance-technologies-llc-sells-43100-shares-of-atricure-inc-atrc.html.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Read More: What is a Swap?
Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.